Paediatric DKA Protocol (ISPAD/European Fluid & Insulin Guidelines, Cerebral Oedema Prevention) and T1DM Maintenance

Paediatric DKA Protocol and Type 1 Diabetes Mellitus Maintenance

Diabetic Ketoacidosis (DKA) is an acute, life-threatening emergency representing the initial manifestation in 25% to 40% of children newly diagnosed with Type 1 Diabetes Mellitus (T1DM) across Europe, and a recurrent hazard during intercurrent illnesses or insulin omission in established patients. Managing paediatric DKA requires understanding the physiological differences between children and adults: paediatric patients are uniquely susceptible to cerebral oedema, the leading cause of DKA-related mortality in childhood. Consequently, clinical guidelines from the International Society for Pediatric and Adolescent Diabetes (ISPAD 2022) and the European Society for Paediatric Endocrinology (ESPE) mandate a structured, cautious rehydration and insulin titration protocol.

---

Pathophysiology of Type 1 Diabetes Mellitus and DKA

Type 1 Diabetes Mellitus is an organ-specific autoimmune disorder characterized by the progressive, immune-mediated destruction of insulin-secreting pancreatic beta cells within the islets of Langerhans.

Genetic Susceptibility and Immunological Markers

• Genetic Architecture: Strongest susceptibility maps to the major histocompatibility complex (MHC) class II region on chromosome 6p21, specifically alleles HLA-DR3-DQ2 and HLA-DR4-DQ8. Over 90% of European children with T1DM carry at least one of these high-risk heterodimers.
• Islet Autoantibodies: These markers help confirm the autoimmune classification of diabetes:
  • Anti-Glutamic Acid Decarboxylase (anti-GAD65): Most prevalent antibody, frequently persisting for years after diagnosis.
  • Anti-Islet Antigen 2 (anti-IA2): Directed against protein tyrosine phosphatase-like protein; correlates with rapid progression.
  • Anti-Zinc Transporter 8 (anti-ZnT8): Highly specific marker targeting the secretory granule zinc transporter.
  • Islet Cell Cytoplasmic Antibodies (ICA): Detected via indirect immunofluorescence against pancreatic sections.

                                  [Autoimmune Beta-Cell Destruction]
                                                  |
                                  [Absolute Insulin Deficiency]
                                                  |
         +----------------------------------------+----------------------------------------+
         |                                                                                 |
[Counter-Regulatory Surge]                                                        [Impaired Glucose Uptake]
(Glucagon, Adrenaline, Cortisol, GH)                                                       |
         |                                                                        [Severe Hyperglycemia]
         +----------------------------------------+                                        |
                                                  |                               [Glucosuria & Osmotic Diuresis]
                                    [Unrestrained Lipolysis]                               |
                                                  |                               [Profound Dehydration &]
                                    [Massive Free Fatty Acid Flux]                [Electrolyte Depletion]
                                                  |
                                    [Hepatic Ketogenesis]
                             (Acetoacetate & Beta-Hydroxybutyrate)
                                                  |
                                    [Metabolic Ketoacidosis]

The Ketoacidotic Metabolic Cascade

When functional beta-cell mass drops below 10% to 20%, absolute insulin deficiency combines with a massive compensatory surge of counter-regulatory stress hormones (glucagon, adrenaline, cortisol, and growth hormone):

1. Hyperglycemia: Unopposed glucagon drives hepatic glycogenolysis and accelerated gluconeogenesis using amino acids and glycerol substrates. Concurrently, peripheral glucose utilization by skeletal muscle and adipose tissue is markedly reduced, driving blood glucose well above the renal threshold (~10 mmol/L or 180 mg/dL).
2. Osmotic Diuresis and Dehydration: Glucosuria causes profound osmotic diuresis, with extensive urinary wasting of free water, sodium, potassium, chloride, magnesium, and phosphate. This produces hypovolemia, hyperosmolality, and reduced glomerular filtration.
3. Accelerated Lipolysis and Ketogenesis: Insulin deficiency disinhibits hormone-sensitive lipase in adipose tissue, releasing vast quantities of free fatty acids (FFAs) into the portal circulation. In hepatocytes, carnitine palmitoyltransferase-1 (CPT-1) channels FFAs into mitochondrial beta-oxidation, generating excess acetyl-CoA that is converted into ketone bodies: acetoacetate and beta-hydroxybutyrate.
4. High Anion Gap Metabolic Acidosis: Dissociation of ketone acids generates hydrogen ions that consume extracellular bicarbonate ($HCO_3^-$), producing severe metabolic acidosis with an elevated serum anion gap:$\text{Anion Gap} = [\text{Na}^+] - ([\text{Cl}^-] + [\text{HCO}_3^-]) > 16\text{ mmol/L}$

---

Diagnostic Criteria and Clinical Severity Grading

Biochemical confirmation of paediatric DKA requires fulfillment of the classic diagnostic triad:

1. Hyperglycemia: Blood glucose $> 11.0\text{ mmol/L}$ (~$200\text{ mg/dL}$)
2. Metabolic Acidosis: Venous blood gas $\text{pH} < 7.30$ OR serum bicarbonate $< 18.0\text{ mmol/L}$
3. Ketoacidosis: Blood beta-hydroxybutyrate $\ge 3.0\text{ mmol/L}$ OR moderate-to-large urine ketonuria ($\ge 2+$)

Severity Classification

Grade severity by venous pH or serum bicarbonate on presentation; use the more severe category if the results differ:

---

ISPAD / European Fluid Resuscitation Protocol

Restore circulation first, then replace the estimated deficit with maintenance over 24–48 hours. In the PECARN trial, tested faster/slower and 0.45%/0.9% saline regimens did not differ in cerebral-injury risk. Follow an established protocol, reassess frequently and avoid unnecessary fluid restriction.

Step 1: Initial Volume Expansion

• In volume-depleted children without shock, give 10–20 mL/kg of 0.9% saline over 20–30 minutes; use 20 mL/kg when tissue perfusion is poor.
• In shock, restore circulation rapidly with 20 mL/kg of 0.9% saline aliquots, reassessing after each and repeating when necessary.
• Account for fluids already given before calculating the remaining deficit and ongoing replacement.

Step 2: Calculating Deficit and Maintenance Fluids

After initial volume expansion, choose a 24–48-hour replacement schedule. The following calculation illustrates a 48-hour schedule: $\text{Total Fluid over 48 Hours} = \text{Remaining Fluid Deficit} + \text{48-Hour Maintenance Requirement}$

1. Estimate Fluid Deficit:
   • Mild DKA: Assume 5% ($50\text{ mL/kg}$); moderate DKA: 7% ($70\text{ mL/kg}$).
   • Severe DKA: Assume 10% ($100\text{ mL/kg}$).
   • Subtract the initial expansion volume already given from the estimated deficit to determine the remaining deficit.
2. Calculate Maintenance Fluid:
   • Use the standard Holliday-Segar method:
     • First $10\text{ kg}$: $100\text{ mL/kg/day}$
     • Next $10\text{ kg}$ ($11\text{--}20\text{ kg}$): Add $50\text{ mL/kg/day}$
     • Each $\text{kg} > 20\text{ kg}$: Add $20\text{ mL/kg/day}$ (maximum $2,000\text{--}2,500\text{ mL/day}$)
   • Multiply the daily maintenance by 2 to yield the 48-hour requirement.
3. Hourly Infusion Rate:
   • Evenly divide the sum of remaining deficit and 48-hour maintenance across 48 hours: $\text{Hourly Fluid Rate (mL/h)} = \frac{\text{Remaining Deficit (mL)} + \text{48-h Maintenance (mL)}}{48\text{ hours}}$

---

Insulin Therapy: The Strict 1-Hour Delay Rule

  [Hour 0: Begin Initial Fluid Volume Expansion]
                            |
                   [DO NOT GIVE INSULIN]
                            |
  [Hour >=1: Reassess Perfusion and Potassium]
                            |
        +-------------------+-------------------+
        |                                       |
  [Serum K+ >= 3.5 mmol/L]              [Serum K+ < 3.5 mmol/L]
        |                                       |
  [START CONTINUOUS INSULIN]            [HOLD INSULIN INFUSION]
  - Soluble regular insulin              - Add 40 mmol/L KCl to IV fluids
  - Dose: 0.05 to 0.1 units/kg/h        - Wait until K+ >= 3.5 mmol/L
  - NO INTRAVENOUS BOLUS!                - Then start insulin infusion

The Mandatory 1-Hour Delay

Insulin therapy must STRICTLY BE DELAYED until at least 1 hour AFTER intravenous fluid rehydration has commenced. Rationale:

• Intravenous fluid expansion alone restores renal perfusion, increases urinary glucose excretion, and blunts counter-regulatory hormones, smoothly dropping blood glucose by 3 to 5 mmol/L/hour before insulin is introduced.
• Insulin given before circulation is supported can reduce intravascular volume through falling glucose and osmotic pressure, worsen hypokalaemia and precipitate circulatory compromise.
• Start insulin after initial volume expansion. Earlier insulin has been associated with cerebral injury, and insulin can worsen hypokalaemia or compromise perfusion if given before circulation is supported.

Insulin Dosing and Delivery

• Continuous Intravenous Infusion: Unbuffered soluble (regular) insulin at 0.05 to 0.1 units/kg/hour (e.g., 50 units Actrapid in 50 mL 0.9% saline, running at $0.05\text{--}0.1\text{ mL/kg/hour}$).
• In young children (<5 years) or mild/moderate DKA, a lower dose of 0.05 units/kg/hour is preferred to achieve a controlled glycemic decline.
• NO INITIAL INTRAVENOUS INSULIN BOLUS: It is unnecessary, can precipitate circulatory compromise through a rapid fall in osmotic pressure, and can exacerbate hypokalaemia.

Glucose Maintenance and Addition of Dextrose

• The therapeutic goal of insulin is to halt lipolysis and reverse ketoacidosis, not simply normalize blood glucose.
• Target rate of glucose decline: 3 to 5 mmol/L/hour (avoid dropping faster than $5\text{ mmol/L/hour}$ or $90\text{ mg/dL/hour}$).
• When blood glucose drops below 14 to 17 mmol/L (250 to 300 mg/dL):
  • Continue insulin to suppress ketogenesis. Add dextrose; reduce insulin if hypoglycaemia or hypokalaemia persists despite appropriate treatment, while following ketone clearance.
  • Immediately add 5% Dextrose (and subsequently 10% Dextrose if necessary) to the IV fluids.
  • The "two-bag system" (one bag of $0.9\%\text{ NaCl} + \text{KCl}$, second bag of $10\%\text{ Dextrose} + 0.9\%\text{ NaCl} + \text{KCl}$) allows rapid bedside titration of glucose delivery while keeping total fluid and insulin infusion rates constant.
  • Maintain blood glucose between 8 and 12 mmol/L (150 to 220 mg/dL) until ketoacidosis resolves.

---

Potassium and Electrolyte Management

Children with DKA suffer from profound total body potassium depletion (typically 3 to 6 mmol/kg deficit) caused by urinary potassium wasting during osmotic diuresis and gastrointestinal losses from vomiting.

The Paradoxical Serum Potassium

• Despite massive total body deficits, initial serum potassium levels are frequently normal or elevated (e.g., 5.0 to 6.5 mmol/L). This occurs because:
  • Extracellular hyperosmolality pulls water and potassium out of cells.
  • Intracellular acidosis causes exchange of intracellular potassium for extracellular hydrogen ions.
  • Absence of insulin prevents normal Na+/K+-ATPase-mediated cellular potassium uptake.

Replacement Protocol

• If serum potassium is normal or elevated (<5.5 mmol/L): Add 40 mmol/L Potassium Chloride (KCl) (or a 50:50 mixture of potassium chloride and potassium phosphate) to the IV fluids as soon as urine output is established or after initial rehydration.
• If serum potassium is $< 3.5\text{ mmol/L}$ at baseline: Add 40 mmol/L KCl immediately and HOLD insulin therapy until potassium rises above $3.5\text{ mmol/L}$. Administering insulin during severe hypokalemia drives remaining potassium into cells, triggering fatal cardiac arrhythmias (ventricular fibrillation, asystole).
• If serum potassium is $> 5.5\text{ mmol/L}$: Defer potassium in IV fluids; monitor hourly and start 40 mmol/L KCl as soon as potassium falls below $5.5\text{ mmol/L}$.

---

Cerebral Oedema: Recognition and Bedside Emergency Management

Cerebral oedema develops in 0.5% to 1% of paediatric DKA episodes and accounts for 60% to 90% of all DKA-related deaths. The condition typically manifests between 4 and 12 hours into treatment, during the period of maximal biochemical and osmolar shift.

High-Risk Predictors for Cerebral Oedema

• Younger age (<5 years) and newly diagnosed Type 1 diabetes
• Greater severity of presentation: lower venous pH ($<7.10$), higher baseline serum urea / BUN, lower bicarbonate
• Administration of an initial intravenous insulin bolus
• Bicarbonate administration has been associated with cerebral injury.

Corrected sodium helps interpret water balance: $[\text{Corrected Na}^+] = [\text{Measured Na}^+] + 1.6 \times [(\text{Glucose} - 5.5) / 5.5]$. Follow sodium trends with the clinical response; ISPAD 2022 does not require sodium to rise routinely as glucose falls.

Diagnostic Warning Signs

Immediate Emergency Pharmacotherapy

1. Hyperosmolar Therapy (Choose either agent immediately):
   • Hypertonic 3% Saline: 2.7 to 5.0 mL/kg administered IV over 10 to 15 minutes. (Preferred in many European tertiary centres; maintains systemic intravascular volume while drawing water from brain parenchyma).
   • 20% Mannitol: 0.5 to 1.0 g/kg ($2.5\text{ to }5.0\text{ mL/kg}$) administered IV over 15 to 20 minutes.
   • Repeat the dose in 30 minutes if there is no clinical improvement.
2. Supportive Bedside Actions:
   • Elevate the head of the bed to 30 degrees in the midline.
   • Adjust IV fluids to maintain normal blood pressure while avoiding excessive administration. Avoid hypotension, which compromises cerebral perfusion; seek immediate intensive-care support.
   • Support airway and oxygenation; obtain expert help if intubation is needed. Match ventilation to the compensation expected for the metabolic acidosis and avoid excessive hypocapnia; abrupt loss of compensation also worsens acidosis.

---

Outpatient T1DM Maintenance and Technology

After clinical improvement and resolution of ketosis (beta-hydroxybutyrate $<1.0\text{ mmol/L}$ or a closed anion gap), transition to subcutaneous insulin. Residual hyperchloraemic acidosis need not delay transition. Give rapid-acting subcutaneous insulin 15–30 minutes before stopping IV insulin; basal insulin requires a longer overlap.

Subcutaneous Regimens

• Multiple Daily Injections (MDI): Basal-bolus regimen consisting of once- or twice-daily long-acting analogue (Insulin Glargine, Degludec, or Detemir) providing 40% to 50% of total daily dose, plus rapid-acting analogue (Insulin Aspart, Lispro, or Glulisine) before meals calculated based on carbohydrate ratios and insulin sensitivity factors.
• Continuous Subcutaneous Insulin Infusion (CSII / Insulin Pumps): Continuous basal infusion of rapid-acting insulin with programmed boluses. Modern Hybrid Closed-Loop (AID) Systems integrate continuous glucose monitors (CGM) with predictive algorithms that automatically modulate basal insulin delivery and administer micro-boluses, achieving superior glycemic control.

Glycemic Targets (ISPAD Guidelines)

• Target HbA1c (ISPAD 2024): $\le6.5\%$ (48 mmol/mol) with advanced technology and support when safely achievable; otherwise $\le7.0\%$ (53 mmol/mol). Individualize to hypoglycaemia risk and treatment burden.
• Continuous Glucose Monitoring (CGM) Metrics:
  • Time in Range (TIR, 3.9–10.0 mmol/L / 70–180 mg/dL): $> 70\%$
  • Time Below Range (TBR, <3.9 mmol/L / <70 mg/dL): $< 4\%$
  • Time in Clinically Important Hypoglycaemia (<3.0 mmol/L / <54 mg/dL): $< 1\%$

Acute Hypoglycemia Protocol

• Hypoglycaemia in a conscious child able to swallow:
  • Give approximately 0.3 g/kg of fast-acting glucose (e.g., 9 g for 30 kg; about 15 g for ≥50 kg). A smaller amount may suffice with automated insulin delivery.
  • Recheck glucose after 15 minutes; repeat treatment if still low.
  • Give additional carbohydrate if needed to prevent recurrence when a meal is not imminent.
• Severe Hypoglycemia (unconscious, convulsing):
  • Outpatient Emergency: Intramuscular (IM) Glucagon:
    • Body weight $<25\text{ kg}$: 0.5 mg IM
    • Body weight $\ge25\text{ kg}$: 1.0 mg IM
    • Alternative: Intranasal Glucagon powder (Baqsimi): 3 mg into one nostril, authorized in the EU for age $\ge1\text{ year}$.
  • In-Hospital Emergency: Intravenous 10% Dextrose bolus of 2.0 to 5.0 mL/kg infused over 5 to 10 minutes, followed by maintenance 10% dextrose.